MTOR and hepatocellular carcinoma: Given that mTOR pathway inhibits lysosomal degradation [19] and Rnaseh2c-cKO was linked to KEGG term “Lysosome” (Fig. S1C), while Rnaseh2c-cKO inhibited Traf3ip1 transcriptionally (Fig. 2A–D, S2), we proposed that the RNASEH2C-TRAF3IP1 axis enhances lysosomal degradation of a specific protein to inhibit macrophage antigen presentation in HCC.